ʻO ka Polysaccharide mai Chlorella (PFC), ma ke ʻano he polysaccharide kūlohelohe, ua huki nui ʻia ka manaʻo mai nā mea akamai i nā makahiki i hala iho nei ma muli o kona mau pono o ka haʻahaʻa haʻahaʻa, nā hopena ʻaoʻao haʻahaʻa, a me nā hopena ākea. Ua hōʻoia mua ʻia kāna mau hana i ka hoʻohaʻahaʻa ʻana i nā lipids koko, anti-tumor, anti-inflammatory, anti Parkinson's, anti-aging, etc. i nā hoʻokolohua in vitro a me in vivo. Eia nō naʻe, aia nō kahi hakahaka i ka noiʻi ʻana ma PFC ma ke ʻano he modulator pale kanaka.

ʻO nā pūnaewele Dendritic (DC) nā pūnaewele hōʻike antigen ikaika loa i loko o ke kino o ke kanaka. He liʻiliʻi loa ka helu o nā DC i loko o ke kino o ke kanaka, a hoʻohana pinepine ʻia kahi kumu hoʻohālike hoʻokomo cytokine i hoʻopili ʻia i loko o vitro, ʻo ia hoʻi nā DC i loaʻa mai nā cell mononuclear koko peripheral kanaka (moDC). Ua hōʻike mua ʻia ke kumu hoʻohālike DC i hoʻokomo ʻia i loko o vitro i ka makahiki 1992, ʻo ia ka ʻōnaehana hoʻouluulu kuʻuna no nā DC. Ma ke ʻano laulā, pono ka mahi ʻana no 6-7 mau lā. Hiki ke hoʻoulu ʻia nā pūnaewele iwi ʻiole me ka granulocyte macrophage colony-stimulating factor (GM-CSF) a me interleukin (IL) -4 e loaʻa ai nā DC immature (PBS group). Hoʻohui ʻia nā Cytokines ma ke ʻano he stimuli makua a hoʻoulu ʻia no 1-2 mau lā e loaʻa ai nā DC makua. Ua hōʻike ʻia kekahi noiʻi ʻē aʻe ua hoʻoulu ʻia nā pūnaewele CD14+ kanaka i hoʻomaʻemaʻe ʻia me ka interferon - β (IFN - β) a i ʻole IL-4 no 5 mau lā, a laila hoʻoulu ʻia me ka tumor necrosis factor-a (TNF-a) no 2 mau lā e loaʻa ai nā DC me ka hōʻike kiʻekiʻe o CD11c a me CD83, nona ka hiki ke hoʻolaha i ka hoʻolaha ʻana o nā pūnaewele allogeneic CD4+T a me nā pūnaewele CD8+T. He nui nā polysaccharides mai nā kumu kūlohelohe i loaʻa ka hana immunomodulatory maikaʻi loa, e like me nā polysaccharides mai nā halo shiitake, nā halo gill split, nā halo Yunzhi, a me Poria cocos, i hoʻohana ʻia i ka hana lapaʻau. Hiki iā lākou ke hoʻomaikaʻi maikaʻi i ka hana pale o ke kino, hoʻonui i ka pale ʻana, a lawelawe ma ke ʻano he adjuvant therapies no ka mālama ʻana i ka tumor. Eia nō naʻe, he kakaikahi nā hōʻike noiʻi e pili ana iā PFC ma ke ʻano he modulator pale kanaka. No laila, hana kēia ʻatikala i ka noiʻi mua e pili ana i ke kuleana a me nā ʻano hana pili o PFC i ka hoʻolaha ʻana i ka oʻo ʻana o nā moDC, i mea e loiloi ai i ka hiki o PFC ma ke ʻano he modulator pale kūlohelohe.

Ma muli o ka haʻahaʻa loa o nā DC i loko o nā ʻiʻo kanaka a me ke kiʻekiʻe o ka mālama ʻana i nā ʻano ma waena o nā DC ʻiole a me nā DC kanaka, i mea e hoʻoponopono ai i nā pilikia noiʻi i hoʻokumu ʻia e ka hana DC haʻahaʻa, ua aʻo ʻia nā hiʻohiʻona hoʻokomo in vitro o nā DC i loaʻa mai nā cell mononuclear koko peripheral kanaka, hiki ke loaʻa nā DC me ka immunogenicity maikaʻi i loko o kahi manawa pōkole. No laila, ua hoʻohana kēia haʻawina i ke ʻano kuʻuna o ka hoʻoulu ʻana i nā DC kanaka ma vitro: ka mahi ʻana i ka rhGM CSF a me ka rhIL-4 in vitro, ka hoʻololi ʻana i ka medium i kēlā me kēia lā ʻē aʻe, a me ka loaʻa ʻana o nā DC ʻōpiopio i ka lā 5; I ka lā 6, ua hoʻohui ʻia nā nui like o PBS, PFC, a me LPS e like me ka hui ʻana a ua mahi ʻia no 24 mau hola ma ke ʻano he protocol moʻomeheu no ka hoʻoulu ʻana i nā DC i loaʻa mai nā cell mononuclear koko peripheral kanaka.

Loaʻa i nā polysaccharides i loaʻa mai nā huahana kūlohelohe nā pono o ka haʻahaʻa haʻahaʻa a me ke kumukūʻai haʻahaʻa e like me nā immunostimulants. Ma hope o nā hoʻokolohua mua, ua ʻike kā mākou hui noiʻi e hoʻonui nui ana ʻo PFC i ka māka makua CD83 ma ka ʻili o nā cell mononuclear koko peripheral kanaka i hoʻokomo ʻia i loko o vitro. Ua hōʻike nā hopena cytometry kahe ua hopena ka hana ʻana o PFC ma kahi ʻano o 10 μ g/mL no 24 mau hola i kahi hōʻike kiʻekiʻe o ka māka makua CD83 ma ka ʻili o DCs, e hōʻike ana ua komo nā DCs i kahi kūlana makua. No laila, ua hoʻoholo kā mākou hui noiʻi i ka hoʻolālā hoʻokomo a me ke komo ʻana i loko o vitro. He biomarker makua koʻikoʻi ʻo CD83 ma ka ʻili o DCs, ʻoiai ʻo CD86 e lawelawe ana ma ke ʻano he mole hoʻoulu koʻikoʻi ma ka ʻili o DCs, e hana ana ma ke ʻano he hōʻailona ʻelua no ka hoʻoulu ʻana i nā cell T. ʻO ka hoʻonui ʻia ʻana o nā biomarkers ʻelua CD83 a me CD86 e hōʻike ana e hoʻolaha ana ʻo PFC i ka oʻo ʻana o nā DCs i loaʻa mai i nā cell mononuclear koko peripheral kanaka, e hōʻike ana e hiki i ka PFC ke hoʻonui i ka pae huna o nā cytokines ma ka ʻili o DCs. No laila, ua loiloi kēia haʻawina i nā pae o nā cytokines IL-6, TNF-a, a me IL-10 i hūnā ʻia e DCs me ka hoʻohana ʻana iā ELISA. Pili loa ʻo IL-10 i ka hoʻomanawanui ʻana o ka pale ʻana o DCs, a ʻo DCs me ka hoʻomanawanui ʻana o ka pale ʻana e hoʻohana pinepine ʻia i ka mālama ʻana i ka maʻi puʻupuʻu, e hāʻawi ana i nā manaʻo therapeutic hiki no ka hoʻomanawanui ʻana o ka pale ʻana i ka hoʻoili ʻana o nā ʻāpana; He kuleana koʻikoʻi ka ʻohana 1L-6 i ka pale ʻana o ka innate a me ka adaptive, hematopoiesis, a me nā hopena anti-inflammatory; Aia nā haʻawina e hōʻike ana e komo pū ana ʻo IL-6 a me TGF β i ka hoʻokaʻawale ʻana o nā cell Th17; Ke hoʻouka ʻia ke kino e kahi maʻi, ʻo ka TNF-a i hana ʻia e DCs ma ke ʻano he kumu hoʻoulu autocrine e hoʻolaha i ka hoʻoulu ʻana o DC. ʻO ka pale ʻana iā TNF-a e hoʻokomo i nā DCs i kahi pae ʻōpiopio, e pale ana iā lākou mai ka hoʻokō piha ʻana i kā lākou hana hōʻike antigen. Ua hōʻike ka ʻikepili ELISA ma kēia haʻawina ua hoʻonui nui ʻia ka pae huna o IL-10 i ka hui PFC i hoʻohālikelike ʻia me nā hui ʻelua ʻē aʻe, e hōʻike ana e hoʻonui ʻo PFC i ka hoʻomanawanui ʻana o ka pale ʻana o DCs; ʻO ka hoʻonui ʻia ʻana o nā pae huna o IL-6 a me TNF-a e hōʻike ana he hopena paha ko PFC i ka hoʻonui ʻana i ka DC e hoʻolaha i ka hoʻokaʻawale ʻana o nā cell T.